Minapharm Pharmaceuticals results, Q2 2023
Net profit, assets, equity and cash flow for Q2 2023, against the same period a year earlier, from the published financial statements.
Net profit-31.99 millionEGP · −105.2% vs the same period a year earlier
Total assets8.7 billionEGP · +27.9% vs the same period a year earlier
Shareholders' equity3.52 billionEGP · +15.7% vs the same period a year earlier
Operating cash flow106 millionEGP · −81.2% vs the same period a year earlier
In short
- Minapharm Pharmaceuticals's net profit for Q2 2023 was about -31.99 million EGP, down −105.2% from 613 million EGP in Q2 2022.
- Total assets at the end of Q2 2023 were about 8.7 billion EGP, and shareholders' equity about 3.52 billion EGP.
- Operating cash flow for Q2 2023 was positive at 106 million EGP.
Key lines against the same period a year earlier
This periodQ2 2022Change
Net profit-31.99 million613 million−105.2%
Gross profit1.41 billion1.61 billion−12.8%
Total assets8.7 billion6.81 billion+27.9%
Total liabilities5.19 billion3.77 billion+37.7%
Shareholders' equity3.52 billion3.04 billion+15.7%
Total liabilities and equity8.7 billion6.81 billion+27.9%
Operating cash flow106 million562 million−81.2%
Investing cash flow-1.41 billion-1.16 billion−21.2%
Financing cash flow1.51 billion994 million+52.1%
Net change in cash209 million179 million+16.7%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Minapharm Pharmaceuticals's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy